LDA has assembled articles on Covid-19 and Lyme disease to help guide you and your family and friends as we enter the “new normal.”
Disclaimer: The Lyme Disease Association Inc. (LDA) provides this information as a public service. LDA does not necessarily endorse any of the studies or other articles in this section. Viewers need to consult with physicians or other professionals on any healthcare issues.
According to a Dartmouth-Hitchcock press release, Dartmouth-Hitchcock Medical Center (DHMC) was one of 18 sites that conducted patient trials with lenzilumab and found this drug to be a safe, well-tolerated, and highly effective treatment against COVID-19.